ApoB counts the particles that actually enter the artery wall; LDL-C measures the cholesterol they carry. When the two disagree — common with insulin resistance — ApoB is the one that predicts risk. Ask for it.
Side by side
| Feature | ApoB | LDL cholesterol (LDL-C) |
|---|---|---|
| Measures | Number of atherogenic particles (one ApoB per particle) | Cholesterol mass inside LDL particles |
| Predicts risk | Better, especially with high triglycerides or insulin resistance | Reasonable when particles are 'normal' sized |
| Reference / target | Ref <130 · target <80 mg/dL | Ref <130 · target varies by risk |
| Ordered routinely? | Rarely | Always |
| Cost | Low add-on | Standard |
The evidence
Multiple large analyses show ApoB outperforms LDL-C for predicting cardiovascular events, and guidelines increasingly recognize it. The discordance matters most for people with metabolic syndrome, where LDL-C can look fine while particle number is high.
Who each may suit
- You have high triglycerides, insulin resistance or a family history
- Your LDL-C is borderline and you want a clearer read
- You're tracking a plan
- A standard panel is all that's available
- Your triglycerides are low and LDL-C is clearly low or high
Cautions
Neither number is the whole picture: Lp(a) (test once), hs-CRP, blood pressure and insulin complete it. Treatment thresholds are a decision with your clinician.
Cost
ApoB is an inexpensive add-on to a lipid panel; Cellular Bloodwork Analysis includes it.
Educational, not medical advice. Reviewed by the medical advisory board; last reviewed Sep 2026. Standards
